Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin

June 18, 2009

LAIYANG, China, June 18 /PRNewswire-Asia-FirstCall/ — Jiangbo
Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: JGBO) (the “Company”,
“Jiangbo”), a U.S. pharmaceutical company with its principal operations in the
People’s Republic of China
, today announced that it will attend the China New
Drugs Trade Fair from June 26 to 28, 2009 at Tianjin Binhai International
Convention & Exhibition Center, and also plans to launch a new promotional
campaign for its recently acquired Laiyang Pear Cough Syrup.

Jiangbo plans to promote its brand at the trade fair to increase the
popularity of its Traditional Chinese Medicine (TCM) products. The Company
will promote the portfolio of TCM products it acquired by purchasing Hongrui
Pharmaceutical Company in early 2009 to its existing customers, and speak with
new potential distributors.

Laiyang City is famous for its pears. “Laiyang Pear” is a trademark for
place of origin which is registered with the Chinese National Industrial and
Commercial Bureau. In production by Jiangbo since April of 2009, Laiyang Pear
Cough Syrup is made from Laiyang Pears and is used to relieve coughs and
remove phlegm arising from colds or other ailments. The Company believes that
Laiyang Pear Cough Syrup tastes much better than alternative cough syrups. The
cough syrup’s pear taste makes it especially popular among children.

As a leading manufacturer using Laiyang Pears in a cough syrup, Jiangbo
intends to leverage its location in Laiyang and extensive sales network to
become the market leader for this type of cough syrup.

“We look forward to attending the trade fair. We plan to renew old
contacts, and hope to develop new relationships with distributors through
which we will increase our TCM sales,” said Mr. Wubo Cao, CEO of Jiangbo.
“Separately, we plan to start an active promotional campaign for our Laiyang
Pear Cough Syrup. The current market size for cough syrups in China is
approximately RMB 5 to 10 billion annually and is rapidly growing. We
currently estimate that our sales of Laiyang Pear Cough Syrup in China will
reach RMB 500 million within the next five years.”

About the 44th China New Drugs Trade Fair

The China New Drugs Trade Fair is a professional forum for individuals and
companies interested in commercializing drugs and new pharmaceutical products
in China. The event will be held June 26 to 28 at the Binhai International
Convention & Exhibition Center in Tianjin, China. The trade fair plays an
important role in connecting “Government, industry, academic research, funding
and service.” More than 70,000 professionals are expected to attend the trade
fair. For more information about the China New Drugs Trade Fair, please visit
http://en.newdrugschina.com .

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the
research, development, production, marketing and sales of pharmaceutical
products in the People’s Republic of China. Its operations are located in
Eastern China in an Economic Development Zone in Laiyang City, Shandong
province. Jiangbo is a major pharmaceutical company in China producing both
western and Chinese herbal-based medical drugs in tablet, capsule, granule,
syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause the
Company’s actual results and financial position to differ materially from
those included within the forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from anticipated or predicted results, and reported results should
not be considered as an indication of future performance. The potential risks
and uncertainties include, among others, the Company’s ability to obtain raw
materials needed in manufacturing, the continuing employment of key employees,
the failure risks inherent in testing any new drug, the possibility that
regulatory approvals may be delayed or become unavailable, patent or licensing
concerns that may include litigation, direct competition from other
manufacturers and product obsolescence. More information about the potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings, available via the United States Securities
and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com


    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com


SOURCE Jiangbo Pharmaceuticals Enterprises, Inc.

Source: newswire

comments powered by Disqus